SCHEMBL25379052

SCHEMBL25379052

c1ccc(Cn2ccc(-c3cccc(-c4cncnc4)c3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
NPC1 O15118 3/20 0.52
ALDH1A1 P00352 3/20 0.52
LMNA P02545 3/20 0.52
HPGD P15428 3/20 0.52
RAB9A P51151 3/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
TEK Q02763 4/20 0.49
EPHB4 P54760 3/20 0.49
MPO P05164 1/20 0.47
KDR P35968 4/20 0.46
CYP19A1 P11511 2/20 0.45
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30561643 1.00 KDM4E (0.52) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL30509994 0.85 MPO (0.48) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL30509990 0.85 MPO (0.48) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL25295323 0.85 MPO (0.48) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL25379538 0.83 KDM4E (0.48) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL25302168 0.83 NPC1 (0.46) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL30510191 0.83 NPC1 (0.46) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL25378454 0.83 ALDH1A1 (0.48) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL30509999 0.83 ALDH1A1 (0.48) KDM4ENPC1ALDH1A1LMNAHPGD
SCHEMBL25376439 0.82 ALDH1A1 (0.46) KDM4ENPC1ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 KDM4E 1163/4885NPC1 2100/4885ALDH1A1 2212/4885
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 KDM4E 1163/4885NPC1 2100/4885ALDH1A1 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.